|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCAIM |
Gene summary for TCAIM |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCAIM | Gene ID | 285343 |
| Gene name | T cell activation inhibitor, mitochondrial | |
| Gene Alias | C3orf23 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R2R9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285343 | TCAIM | LZE4T | Human | Esophagus | ESCC | 1.06e-02 | 7.20e-02 | 0.0811 |
| 285343 | TCAIM | LZE24T | Human | Esophagus | ESCC | 2.84e-09 | 2.89e-01 | 0.0596 |
| 285343 | TCAIM | P2T-E | Human | Esophagus | ESCC | 3.73e-24 | 2.26e-01 | 0.1177 |
| 285343 | TCAIM | P4T-E | Human | Esophagus | ESCC | 5.84e-16 | 4.85e-01 | 0.1323 |
| 285343 | TCAIM | P5T-E | Human | Esophagus | ESCC | 4.33e-03 | 3.77e-02 | 0.1327 |
| 285343 | TCAIM | P8T-E | Human | Esophagus | ESCC | 2.54e-08 | 9.16e-02 | 0.0889 |
| 285343 | TCAIM | P9T-E | Human | Esophagus | ESCC | 4.04e-04 | 9.65e-02 | 0.1131 |
| 285343 | TCAIM | P10T-E | Human | Esophagus | ESCC | 4.28e-15 | 2.36e-01 | 0.116 |
| 285343 | TCAIM | P11T-E | Human | Esophagus | ESCC | 8.07e-04 | 1.63e-01 | 0.1426 |
| 285343 | TCAIM | P12T-E | Human | Esophagus | ESCC | 8.29e-14 | 2.59e-01 | 0.1122 |
| 285343 | TCAIM | P15T-E | Human | Esophagus | ESCC | 6.15e-03 | 1.49e-01 | 0.1149 |
| 285343 | TCAIM | P16T-E | Human | Esophagus | ESCC | 1.78e-05 | 1.21e-01 | 0.1153 |
| 285343 | TCAIM | P20T-E | Human | Esophagus | ESCC | 2.66e-09 | 2.37e-01 | 0.1124 |
| 285343 | TCAIM | P21T-E | Human | Esophagus | ESCC | 5.34e-23 | 4.80e-01 | 0.1617 |
| 285343 | TCAIM | P22T-E | Human | Esophagus | ESCC | 2.76e-03 | 2.15e-02 | 0.1236 |
| 285343 | TCAIM | P23T-E | Human | Esophagus | ESCC | 2.65e-08 | 2.11e-01 | 0.108 |
| 285343 | TCAIM | P24T-E | Human | Esophagus | ESCC | 2.00e-07 | 2.29e-01 | 0.1287 |
| 285343 | TCAIM | P26T-E | Human | Esophagus | ESCC | 2.70e-20 | 2.02e-01 | 0.1276 |
| 285343 | TCAIM | P27T-E | Human | Esophagus | ESCC | 2.09e-10 | 1.66e-01 | 0.1055 |
| 285343 | TCAIM | P28T-E | Human | Esophagus | ESCC | 1.01e-12 | 2.47e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCAIM | SNV | Missense_Mutation | novel | c.472N>A | p.Asp158Asn | p.D158N | Q8N3R3 | protein_coding | tolerated(0.55) | benign(0.003) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
| TCAIM | SNV | Missense_Mutation | c.1177G>A | p.Asp393Asn | p.D393N | Q8N3R3 | protein_coding | tolerated(0.14) | probably_damaging(0.974) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR | |
| TCAIM | SNV | Missense_Mutation | novel | c.355N>A | p.Asp119Asn | p.D119N | Q8N3R3 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TCAIM | SNV | Missense_Mutation | c.1018N>A | p.Glu340Lys | p.E340K | Q8N3R3 | protein_coding | deleterious(0.02) | possibly_damaging(0.553) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TCAIM | SNV | Missense_Mutation | c.465N>C | p.Arg155Ser | p.R155S | Q8N3R3 | protein_coding | tolerated(0.74) | benign(0.003) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TCAIM | SNV | Missense_Mutation | c.182N>A | p.Ser61Tyr | p.S61Y | Q8N3R3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TCAIM | SNV | Missense_Mutation | c.901C>T | p.Pro301Ser | p.P301S | Q8N3R3 | protein_coding | tolerated(0.15) | possibly_damaging(0.698) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| TCAIM | SNV | Missense_Mutation | c.502T>C | p.Tyr168His | p.Y168H | Q8N3R3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TCAIM | SNV | Missense_Mutation | novel | c.821N>A | p.Ser274Tyr | p.S274Y | Q8N3R3 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TCAIM | SNV | Missense_Mutation | rs767273410 | c.469N>T | p.Pro157Ser | p.P157S | Q8N3R3 | protein_coding | tolerated(0.88) | benign(0) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |